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Letter to the Editor
A controversial conclusion re-
garding primary extranodal dif-
fuse large B-cell lymphoma
TO THE EDITOR: Recently, primary extranodal non- 
Hodgkin’s lymphoma (NHL) has gained considerable atten-
tion. Many controversies are associated with primary extra-
nodal NHL, mainly due to inadequate and contradictory 
literatures, and lack of uniformity in definition, clin-
icopathological characteristics, and clinical outcomes ac-
cording to the involved sites. Jang et al. put forth prospects 
for further research to evaluate primary extranodal DLBCL 
[1]. Although they concluded that rituximab had no role 
in the treatment of primary extranodal DLBCL, their report 
included several limitations that were obstacles to achieve 
conclusive results.
The diversity in clinical presentation, morphology, im-
munophenotype, and genetic alterations strongly suggest 
that DLBCL belongs to a heterogeneous group of aggressive 
B-cell lymphomas. Extranodal disease is the predominant 
disease manifestation (incidence, about 40%) among DLBCL 
patients. Even in patients with stage I disease, 56% had 
extranodal DLBCL [2]. On the basis of the results of routine 
staging, the authors defined PENL (primary extranodal lym-
phoma) as a lymphoma with no or minor nodal involvement, 
along with a clinically dominant extranodal component. 
The definition of extranodal disease has been controversial, 
particularly in the presence of both nodal and extranodal 
manifestations. The designation of stage III and IV lympho-
mas as PENLs is debatable, since many clinicians consider 
only stage I and II presentations as primary extranodal dis-
ease [3]. For patients in the advanced stage of disease, this 
diagnostic approach may be inappropriate, because many 
extranodal lymphomas can disseminate and vice versa. In 
the above study, patients with stage III or IV disease con-
stituted more than 50% of all subjects. Therefore, this defi-
nition for PENL inevitably introduces a selection bias.
The second controversial issue is the different prognosis 
according to the involved site. López-Guillermo et al. [4] 
reported that the clinical characteristics of nodal and extra-
nodal DLBCLs were heterogeneous. Lymphomas arising 
from two specific sites [Waldeyer's ring (nodal) and gastro-
intestinal region (extranodal)] showed very favorable char-
acteristics at diagnosis (e.g., early stage, absence of bone 
marrow involvement, normal serum LDH level, and low-risk 
IPI), whereas DLBCLs arising in the remaining areas (lymph 
nodes or other extranodal sites) presented with poorer diag-
nostic characteristics. In terms of response to therapy, risk 
of relapse and overall survival, both Waldeyer's ring and 
gastrointestinal lymphomas showed notably better out-
comes than those shown by the other groups [4, 5]. Thus, 
not only the nodal or extranodal presentation, but also in-
volvement of specific sites may be related to particular clin-
icobiological characteristics and disease outcomes. The au-
thors did not provide detailed information about the in-
volved sites and differences in patient's characteristics be-
tween the extranodal and nodal disease groups. Primary 
extranodal DLBCLs, according to the involved site, may 
be considered as different entities with different natural 
histories, therefore, inference from figures should be dealt 
with caution.
Therefore, further research using population-based stud-
ies is needed to achieve conclusive results for the diagnosis 
of primary extranodal DLBCL. Furthermore, the study of 
unresolved issues, including ambiguous definition, different 
clinicobiological characteristics, and gene profiles of primary 
extranodal DLBCL arising from different sites is warranted.
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